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Abstract
Background—Infection with parechovirus type 3 (PeV3) can cause severe neurologic and 
sepsis-like illness in young infants; clinical and epidemiologic descriptions have been limited. We 
aimed to characterize PeV3 illness and explore risk factors for acquisition in a cluster of neonatal 
cases at Children's Mercy Hospital in Kansas City, Missouri.
Methods—Cerebrospinal fluid specimens were obtained from infants aged <180 days who were 
hospitalized with sepsis-like illness or meningitis between June 1 and November 1, 2014. PeV-
positive specimens were sequenced at the Centers for Disease Control and Prevention. We 
reviewed the medical and birth charts of the infants and performed face-to-face parent interviews. 
We analyzed characteristics according to infant age and intensive care admission status.
Results—We identified 35 cases of PeV infection in infants aged 5 to 56 days. Seven infants 
required intensive care (median age, 11 days vs 27 days among those who did not require intensive 
care; P = .0044). Six of these 7 infants had neurologic manifestations consistent with seizures, and 
all 6 of them were treated with acyclovir but subsequently tested negative for herpes simplex virus. 
Virus sequences formed 2 lineages, both of which were associated with severe illness. Half of the 
infants were reported to have household contacts who were ill during the week before onset. 
Infants aged ≤7 days at onset were more likely to have been delivered at the same hospital.
Conclusions—PeV3 can cause severe neurologic illness in neonates, and younger infants are 
more likely to require intensive care. PeV3 should be considered along with herpes simplex virus 
and other pathogens when evaluating young infants with sepsis-like illness or meningitis. More 
Correspondence: C. M. Midgley, PhD, CDC, 1600 Clifton Road NE, Atlanta, GA 30329 (ydk5@cdc.gov). 
Potential conflicts of interest. All authors: No reported conflicts All authors have submitted the ICMJE Form for Potential Conflicts 
of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
HHS Public Access
Author manuscript
J Pediatric Infect Dis Soc. Author manuscript; available in PMC 2018 September 29.Author M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
widespread testing for PeV3 would enable us to gain a better understanding of the clinical scope 
and circulation of this virus.
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The genus Parechovirus in the family Picornaviridae comprises 2 species, Parechovirus A 
(formerly human parechovirus) and Parechovirus B (formerly Ljungan virus) [1]. 
Parechovirus A infections are associated with a variety of clinical manifestations that range 
from asymptomatic [2] to severe and include mild respiratory illness [2], rash [3, 4], 
gastroenteritis [5], myocarditis [6], encephalitis [4], meningitis [7], and sepsis-like illness [7, 
8]. They are thought to be very common in the community [2, 9]; most symptomatic 
infections occur in infants younger than 6 months [10, 11]. Parechovirus A has been 
reported in neonates as young as 2 days [12], but reports of infection in the first week of life 
are rare.
To date, 19 Parechovirus A types have been detected worldwide [1, 13, 14]; parechovirus 
type 1 (PeV1) and PeV3 are typically the most commonly detected virus types [9, 15, 16]. 
Although PeV diagnostics are not widely available in the United States, typed viruses can be 
reported passively to the National Enterovirus Surveillance System (NESS) [17]. During 
2009 to 2013, PeV3 was the most common PeV type reported to the NESS, constituting 
12.3% (223 of 1819) of all PeV and enterovirus reports [17]. Similar to enterovirus 
infections, central nervous system infections with PeV3 typically occur in late summer and 
fall [9, 18].
In August 2014, Children's Mercy Hospital in Kansas City, Missouri (CMKC), notified the 
Centers for Disease Control and Prevention (CDC) of young infants and neonates 
experiencing seizures associated with PeV meningitis; initial sequencing at the CDC 
identified PeV3 in cerebrospinal fluid (CSF). Although PeV3 has been associated with 
sepsis-like illness, meningitis, and encephalitis [18], type-specific data are limited, and the 
epidemiology in very young infants is not well defined. Here, we aim to describe the 
epidemiologic and clinical features of these PeV3 cases and to explore possible risk factors 
for acquisition of infection.
Patients and Methods
Case Definition
CMKC is a large pediatric tertiary referral hospital in Kansas City that serves residents of 
neighboring states. Since 2010 at CMKC, CSF from all infants aged <180 days with signs of 
meningitis or sepsis-like illness and submitted for enterovirus testing have also been 
routinely tested for PeV by reverse-transcriptase polymerase chain reaction (RT-PCR). For 
this investigation, PeV-positive specimens were subsequently typed at the CDC. We defined 
a case-patient as any infant aged <180 days at CMKC with CSF confirmed to be PeV3-
positive according to molecular sequencing results from the CDC between June 1 and 
November 1, 2014.
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Virologic Investigation
PeV RT-PCR—Total nucleic acid (TNA) was extracted from 200 μl of CSF or stool 
suspensions (diluted 1:5 in distilled water) using an easy-MAG automated nucleic acid 
system (BioMérieux, Durham, NC) and eluted in 55 μl of Tris-EDTA buffer. The TNA 
extracted from CSF was tested by a 2-step pan-PeV and pan-entero-virus real-time RT-PCR 
on a 7500 fast real-time PCR system (Applied Biosystems, Foster City, CA) as described 
previously [19]. Specimens that tested PeV positive by RT-PCR at CMKC were 
subsequently sent to the CDC for confirmation and typing.
Virus Typing and Phylogenetic Analysis—At the CDC, TNA was tested by a pan-
PeV nested RT-PCR that targets the PeV VP1 region [20]. Complete VP1 sequences from 
specimens that tested positive were typed [20] and then analyzed by the neighbor-joining 
and maximum-likelihood methods using MEGA version 6.0 [21]. Evolutionary distances 
(Kimura 2-parameter method) were calculated in units of the number of base substitutions 
per site. Five hundred bootstrap replicates were performed. Nucleic acid and deduced amino 
acid genetic distances for complete VP1 nucleotide sequences were calculated from 
alignments produced with MegAlign (DNASTAR 12.3.1, Madison, WI).
Epidemiologic Investigation
Because this investigation was part of a public health response, it was determined to be 
nonresearch by the CDC and therefore not subject to CDC institutional review board review.
Medical Chart Abstraction—For each infant with PeV-positive CSF, we abstracted 
demographic and clinical data from the CMKC medical chart. We collected information on 
symptoms, treatment, clinical course, laboratory findings, and imaging results.
Birth Chart Review—Because some case-patients were aged <2 weeks at illness onset, 
we also performed chart abstractions at the hospital in which the infant was born. We 
collected information regarding the mother's medical history, labor, delivery, and follow-up 
and regarding the infant's delivery and neonatal care. Because our investigation included 
case-patients from both Kansas and Missouri, birth chart reviews were coordinated through 
the appropriate health department. Birth chart review was performed for all case-patients 
identified before August 19, 2014. For case-patients identified after this date, because of 
personnel availability, we abstracted data for only those who were aged <2 weeks at illness 
onset.
Parent Interview—We performed face-to-face structured interviews with case-patients’ 
parents or guardians who were willing to participate. We collected information regarding the 
mother's peripartum period, the infant's health before hospitalization with PeV infection, and 
the infant's surroundings, household contacts, and visits (professional or social) in the week 
before illness. Interviews were coordinated through the Kansas and Missouri state health 
departments. For case-patients identified before August 19, 2014, family members were 
contacted by telephone using contact information from CMKC to establish a time and place 
for the face-to-face interview. We typically conducted interviews at the family home. For 
case-patients identified on or after August 19, 2014, because of personnel availability, 
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families were approached during the infant's hospitalization, and interviews were conducted 
on site at CMKC.
Stool Collection—To assess PeV shedding after illness, we collected soiled diapers from 
case-patients and from their siblings who required diapers, tested the stool for PeV by RT-
PCR, and performed sequencing as described earlier. A single diaper from each case-patient 
was typically collected at the time of family interview, which means that the number of days 
between illness onset and diaper collection was different for each case.
Statistical Analyses—For medical chart abstraction of the infants’ hospitalization period, 
we compared characteristics of infants who were admitted to the intensive care unit (ICU) 
with those who were not. For the assessment of characteristics of acquisition through birth 
chart review and parent interview, we performed basic descriptive analyses and compared 
infants admitted to the ICU with those who were not. Subsequently, because PeV had rarely 
been reported in infants in their first week of life, we also compared characteristics in case-
patients ≤7 days of age at disease onset with those who were older. Differences in 
epidemiologic and clinical characteristics were assessed for significance using the Fisher 
exact or Wilcoxon rank-sum test, as appropriate. All data were analyzed using SAS 9.3 
(SAS Institute, Inc., Cary, NC).
Results
Between June 1 and November 1, 2014, 40 infants at CMKC had PeV-positive CSF. Virus 
typing confirmed that 35 of these 40 infants were positive for PeV3, and 1 infant was 
positive for PeV4. Among the 4 remaining infants, CSF from 3 infants tested negative by 
VP1 RT-PCR, and CSF from 1 infant tested PeV-positive by RT-PCR but no residual 
specimen was available for sequencing.
Epidemiologic and clinical features of the 35 case-patients with PeV3 infection are listed in 
Table 1; all of these infants were hospitalized. Overall, 51% (18 of 35) were male, and the 
median age at illness onset was 24 days (range, 5–56 days). Common symptoms included 
fever (>38.0°C, 91% [32 of 35]), tachycardia (77% [27 of 35]), poor feeding (77% [27 of 
35]), irritability (74% [26 of 35]), mottled skin (37% [13 of 35]), and rash (26% [9 of 34]); 
rash descriptions varied and were frequently nonspecific but included macules and papules 
both centrally and on extremities. In addition, 20% (7 of 35) of the infants had neurologic 
manifestations, including eye deviation and limb stiffening (hereafter referred to as 
seizures), that were consistent with partial or generalized seizures. Peripheral blood and CSF 
cell counts were typical of those previously described for patients with PeV infection [11, 
12, 22]; peripheral white blood cell counts were not elevated, and a lack of CSF pleocytosis 
was found. The median length of stay was 3 days (range, 1–18 days). No deaths were 
reported.
The lone PeV4-positive infant experienced fever and difficulty breathing but did not require 
intensive care and was discharged home after 3 days. The infant was 6 days old at illness 
onset.
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Among the 35 infants hospitalized with PeV3 infection, 8 required oxygen and 7 were 
admitted to the ICU. A comparison of infants admitted to the ICU with those who were not 
is shown in Table 1. All infants admitted to the ICU were aged <3 weeks (median, 11 days; 
range, 5–18 days) and were significantly younger than infants who did not require ICU 
admission (median, 27 days; range, 5–56 days; P = .0044). Tree of the 7 infants who 
required ICU admission experienced difficulty breathing, and 2 of 7 had a temperature of 
<35°C. It should be noted that 6 of the 7 infants who required intensive care experienced 
seizures (as defined earlier); all 6 of them were treated with acyclovir, and CSF samples 
from all of them subsequently tested negative for herpes simplex virus. Magnetic resonance 
imaging was performed for 3 of these 6 infants, and the results were abnormal for all of 
them, with white matter changes noted. Electroencephalography was performed for 2 of the 
6 infants; for 1 infant, cephalopathic changes consistent with severe encephalopathy were 
found, and for the other infant, multifocal epileptiform discharges were seen. The median 
length of stay in the ICU was 4 days (range, 1–17 days). Two of the 7 infants who required 
ICU were discharged on anticonvulsant medication.
Complete PeV3 VP1 sequences were obtained from 35 patient CSF specimens. Phylogenetic 
analyses of these sequences with neighbor-joining and maximum-likelihood algorithms 
(Figure 1) gave similar results and showed 2 PeV3 lineages cocirculating during the 
investigation period. The largest PeV3 lineage (found in 30 patients) shared 97.9% to 100% 
nucleotide identity (NT ID) (99.5%–100% amino acid identity [AA ID]), and the smaller 
PeV3 lineage (5 patients) shared 99.8% to 100% NT ID (100% AA ID). Genetic distances 
between the 2 lineages, using the 35 VP1 sequences, ranged from 94% to 95% NT ID 
(98.5%–99% AA ID). Case-patients who required ICU admission were infected with either 
lineage, as were case-patients who experienced seizures. All PeV3 VP1 sequences acquired 
for this study were submitted to Gen Bank and assigned accession numbers KX356610 
through KX356655.
Stool specimens (n = 18) were available from 17 PeV3 case-patients after discharge from the 
hospital, and 8 of these specimens tested positive for PeV3 (Figure 1); all CSF–stool pairs 
from individual patients exhibited ≥98.8% NT ID. Most infants provided a single stool 
specimen, and time between disease onset and the specimen-collection date varied among 
the infants. All specimens collected <25 days after onset (n = 7) tested positive for PeV3. In 
contrast, only 1 of 11 specimens collected beyond 25 days after disease onset (collected on 
day 43) tested positive for PeV3; the 10 PeV3-negative specimens were collected between 
27 and 73 days after disease onset. One infant provided 2 specimens, 1 on day 24 after 
disease onset, which tested positive for PeV3, and 1 on day 44 after onset, which tested 
negative.
To understand the characteristics of infants with PeV3 infection and their families, we 
performed birth chart reviews and parent interviews (Table 2). One of the 35 case-patients 
with PeV3 infection was born and resided in Texas and was excluded. Among the remaining 
34 case-patients, 26 met our criteria for birth chart review, including 22 case-patients whose 
infection status was detected before August 19, 2014, and 4 case-patients whose infection 
status was detected after this date and were aged <2 weeks at onset. Twenty-two (85%) of 
these 26 birth chart reviews were completed. Parents of 23 (68%) of the 34 case-patients 
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agreed to be interviewed; the median time between illness onset and the interview date was 
24 days (range, 1–74 days). Both birth chart reviews and interviews were available for 16 
cases.
Birth chart reviews to explore mother and child health at delivery were unrevealing; for 
example, most births were uncomplicated, case-patients were not born prematurely, and the 
mothers were not reported as being febrile during delivery or in the week before. Parent 
interviews revealed that almost half of the case-patients (11 of 23) had a household contact 
who was ill during the week before disease onset. Ill contacts (n = 20) typically experienced 
symptoms representative of mild respiratory (n = 15) or gastrointestinal (n = 5) illness or had 
a rash (n = 2); the specific illness of 1 contact was not described. Most (21 of 23) of the 
infants had a household contact aged <11 years; the median age of these contacts was 3 
years (range, 13 months to 10 years). Ten case-patients had a household contact aged <11 
years who was ill during the week before onset. Stool specimens were available from 7 
contacts of 6 case-patients. Siblings of 2 case-patients had PeV3-positive stool, and both 
case-patient (CSF)–sibling (stool) pairs exhibited ≥99.8% NT ID (Figure 1); 1 sibling was 
reported to have developed a rash after the case-patient was discharged from CMKC, and the 
sibling of the other case-patient reported no symptoms. For 4 of the case-patients with PeV3 
infection, a family history of neurological issues was reported, including history of seizures, 
attention-deficit hyperactivity disorder, and multiple sclerosis; 1 of these 4 patients 
experienced seizures during the hospitalization for PeV3 infection.
When we compared PeV3-positive case-patients aged ≤7 days (n = 5; listed in Table 3) with 
older case-patients, no apparent differences were observed in the data from the birth chart 
reviews or parent interviews, apart from the infant's birth hospital. Four (80%) of the 5 
infants whose illness onset occurred in their first week of life were born at the same hospital 
(hospital A) within a period of 34 days. In contrast, only 2 (10%) of 20 case-patients who 
were >7 days old at illness onset were delivered at hospital A. Viruses from the 4 infants 
delivered at hospital A were part of the larger lineage and exhibited ≥99.7% NT ID.
Discussion
We provide here a clinical and epidemiologic description of PeV3 infection in young infants 
and, by typing all available specimens, have provided an in-depth type-specific disease 
characterization. We show that PeV3 can cause severe neurologic illness in neonates and, in 
some cases, associated white matter changes. All infants who required intensive care became 
ill during their first 3 weeks of life and were significantly younger than those who were not 
admitted to the ICU.
Our clinical findings are consistent with data from previous PeV investigations. We found 
that common symptoms during PeV3 infection include fever [7, 9, 11, 12], tachycardia [11], 
poor feeding [7], irritability [7, 9, 11, 12], mottled skin [23], and rash [9]. Severe PeV3 
infections that required intensive care management were more common in younger infants 
(aged <3 weeks) in our investigation, as previously reported for untyped PeV infections [7]. 
We also identified seizures [3, 11, 24] associated with white matter changes as an important 
presentation, which was observed in 7 of 34 infants (6 of 7 in the ICU). As expected, all 
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infants in our investigation who presented with seizures were evaluated for HSV infection 
and empirically treated with intravenous acyclovir. At CMKC, acyclovir treatment was 
stopped once the infant tested negative for HSV and positive for PeV. By comparison, 
CMKC detected only 1 infant (aged <30 days) with central nervous system HSV infection 
during the investigation period. A wider availability of diagnostics for PeV could lead to 
more judicious use of acyclovir in this very young and vulnerable population. Furthermore, 
infection outcomes vary substantially among patients with HSV and those with PeV. Unlike 
the potentially fatal neurologic complications of HSV infection in infants [25], most infants 
in our investigation who were infected with PeV3 were discharged from the hospital in 
healthy condition after several days. Although longer-term neurologic sequelae after PeV 
infection have been observed [7, 26], we did not assess long-term outcomes in this 
investigation. In addition, all case-patients in our investigation survived, although PeV3 
infection has been associated with rare fatalities [27, 28].
Consistent with previous reports that suggested that older siblings might pose a risk for PeV 
exposure [29], results of our parent interviews indicated that almost half of all case-patients 
had ill household contacts aged <11 years. However, data from households without 
recognized PeV3 infection were not available for comparison. Results of previous 
retrospective studies have suggested that PeVs are a common source of illness in the 
community; PeV has been detected in 3% to 17% of CSF specimens from hospitalized 
infants [12, 22, 30, 31], 13% of blood specimens from infants who required intensive care 
for late-onset sepsis [32], 3.7% of plasma specimens from children who presented to an 
emergency department [33], and 16.3% of stool specimens from children who presented to a 
medical center [10]. Despite these high estimates, PeVs often go undetected because of mild 
or asymptomatic presentations [2, 34] combined with limited application of available 
diagnostic tests. Although data on PeV3 circulation are limited, our cases occurred mostly 
within the proposed PeV3 season (late summer and fall) [9, 18].
A subset of case-patients who became ill in their first week of life were of particular 
concern, because infection in this age group had been reported only rarely before this 
investigation. To explore the possibility of perinatal infection, maternal demographics and 
health at delivery were reviewed closely using labor and delivery charts, but this review was 
unrevealing. Maternal age has been suggested to be associated with severity of illness [35], 
but we did not detect such an association.
We noted that 4 of 5 infants aged ≤7 days at illness onset were delivered at hospital A within 
a similar time period. Although it was not possible to distinguish between infections 
acquired in the healthcare setting versus those acquired in the community, this finding 
supports the recently reported possibility of healthcare-associated acquisition of PeV3 
infection [13]. By comparison, it has been known for some years that PeV1 (previously 
named echovirus 22) can be transmitted within healthcare settings and can cause respiratory 
[36] or gastrointestinal [37] illness.
PeVs have been detected in a variety of specimens, including those from respiratory 
secretions [38] and stool [2, 10, 39]. We found that the stool of PeV3 case-patients could test 
positive 43 days after illness onset. By comparison, in infants followed longitudinally in 
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previous investigations, the median duration of shedding was 51 [2] to 58 [39] days. 
Prolonged shedding after symptom resolution highlights the need for constant vigilance in 
infection-prevention and -control practices.
Phylogenetic clustering of the PeV3 VP1 sequences indicated cocirculation of 2 PeV3 
strains, which differed by ≥5% NT ID, among patients treated at CMKC. Cocirculation of 
different PeV3 lineages had not been observed in PeV3 outbreaks previously, but it is 
common in large outbreaks of enterovirus disease [40]. This observation in a local PeV3 
outbreak might be attributable to the large catchment area of CMKC. Severe illness was 
observed in both PeV3 clusters.
Our investigation was subject to several limitations. First, PeV testing is specialized, and its 
availability is limited. By directing testing toward CSF specimens from hospitalized infants 
aged <6 months, CMKC focuses on young infants and the more severe end of the clinical 
spectrum; therefore, the generalizability of these results is unknown. Second, parent 
interviews might have been subject to recall issues, especially for the families of infants who 
became ill earlier in the season. Last, we were not able to sequence 5 of the 40 original CSF 
specimens collected; the 5 infants from whom the specimens were not collected were aged 
≥18 days, but no other differences were noted.
Conclusion
PeV3 should be considered alongside HSV, enteroviruses, and other pathogens as a cause of 
sepsis-like illness and meningitis in young infants. In addition to informing clinical 
management, expanded testing for PeVs might allow for a better understanding of virus 
circulation and disease burden.
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Figure 1. Maximum-likelihood phylogeny of parechovirus type 3 VP1 sequences from patients at 
Children's Mercy Hospital in Kansas City, Missouri, June 1 to November 1, 2014
Sequences from cerebrospinal fluid (CSF) are denoted by solid squares, from stool by solid 
circles, and from sibling stool by hollow circles. Single patient-associated CSF, stool, and 
sibling stool specimens are designated A, B, and C, respectively. Bootstrap values ≥ 80 are 
indicated.
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Table 1
Clinical Characteristics of PeV3-Positive Case-Patients According to the Need for 
Intensive Carea
Variable Admitted to ICU (N = 
7)
Not Admitted to ICU (N 
= 28)
Total (N = 35) P (Fisher's Exact or 
WRS)
Demographics
 Sex, male 4 (57) 14 (50) 18 (51) 1.0000
 Infant age (days) 11 (5–18) 27 (5–56) 24 (5–56) .0044
Febrile illness
 Fever (>38°C) 4 (57) 28 (100) 32 (91) .0053
 If fever, highest temperature (°C) 38.5–39.9 38.3–40.3 38.3–40.3 .6265
 Temperature <35°C 2 (29) 0 (0) 2 (6) .0353
Skin rash 3 (43) 6 (21) 9 (26) .3397
Neurologic illness
 Seizures 6 (86) 1 (4) 7 (20) <.0001
 Bulging fontanelle 0 (0) 1 (4) 1 (3) 1.0000
 Lethargy 1 (14) 2 (7) 3 (9) .4525
 Irritability 5 (71) 21 (75) 26 (74) 1.0000
 Inconsolable crying 0 (0) 3 (11) 3 (9) 1.0000
Respiratory illness
 Cough 0 (0) 5 (18) 5 (14) .5585
 Runny nose 0 (0) 4 (14) 4 (11) .5620
 Sneezing 0 (0) 1 (4) 1 (3) 1.0000
 Diffculty breathing 3 (43) 0 (0) 3 (9) .0053
 Rales/crackles/crepitations 1 (14) 0 (0) 1 (3) .2000
 Retractions/nasal faring 1 (14) 0 (0) 1 (3) .2000
 Respiratory failure 3 (43) 0 (0) 3 (9) .0053
Cardiovascular illness
 Tachycardia 6 (86) 21 (75) 27 (77) 1.0000
 If tachycardic, heart rate (beats/min) 193–200 164–225 164–225 .8376
 Cyanosis 2 (29) 0 (0) 2 (6) .0353
 Mottled skin 2 (29) 11 (39) 13 (37) .6889
 Abnormal heart sounds 1 (14) 6 (21) 7 (20) 1.0000
 Hypotension/shock 1 (14) 1 (4) 2 (6) .3647
Gastrointestinal illness
 Vomiting 2 (29) 6 (21) 8 (23) .6478
 Watery stools 1 (14) 3 (11) 4 (11) 1.0000
 Abdominal distention 1 (14) 5 (18) 6 (17) 1.0000
 Abdominal pain 0 (0) 5 (18) 5 (14) .5585
 Jaundice 2 (29) 0 (0) 2 (6) .0353
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Variable Admitted to ICU (N = 
7)
Not Admitted to ICU (N 
= 28)
Total (N = 35) P (Fisher's Exact or 
WRS)
 Poor feeding 6 (86) 21 (75) 27 (77) 1.0000
 Other symptoms: persistent crying 0 (0) 1 (4) 1 (3) 1.0000
Clinical course
 Oxygen given 6 (86) 2 (7) 8 (23) <.0001
 Intubated 2 (29) 0 (0) 2 (6) .0353
 Treated with acyclovir 7 (100) 9 (32) 16 (46) .0017
 Treated with antibiotics 7 (100) 27 (96) 34 (97) 1.0000
Outcome
 Length of stay (days) 9 (2–18) 3 (1–6) 3 (1–18) .0105
 ICU length of stay (days) 4 (1–17) — — —
 Death 0 (0) 0 (0) 0 (0) —
Abbreviations: ICU, intensive care unit; WRS, Wilcoxon Rank Sum; PeV3, parechovirus type 3.
aValues shown are number (percent) or median (range). The following symptoms were collected but not reported for any infants: redness in the 
hands and feet, ulcers or lesions in the mouth, myoclonic jerk, tremor, limb weakness, stiff neck, cranial nerve palsy, secretions, wheezing, frothy 
secretions from mouth, hemoptysis, bradycardia, variable heart rate, arrhythmia, constipation, conjunctivitis, bleeding, and lymphadenopathy.
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